These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35596878)

  • 1. Ganaxolone: First Approval.
    Lamb YN
    Drugs; 2022 Jun; 82(8):933-940. PubMed ID: 35596878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
    Knight EMP; Amin S; Bahi-Buisson N; Benke TA; Cross JH; Demarest ST; Olson HE; Specchio N; Fleming TR; Aimetti AA; Gasior M; Devinsky O;
    Lancet Neurol; 2022 May; 21(5):417-427. PubMed ID: 35429480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.
    Carter RB; Wood PL; Wieland S; Hawkinson JE; Belelli D; Lambert JJ; White HS; Wolf HH; Mirsadeghi S; Tahir SH; Bolger MB; Lan NC; Gee KW
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1284-95. PubMed ID: 9067315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures.
    Sperling MR; Klein P; Tsai J
    Epilepsia; 2017 Apr; 58(4):558-564. PubMed ID: 28230252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy.
    Pieribone VA; Tsai J; Soufflet C; Rey E; Shaw K; Giller E; Dulac O
    Epilepsia; 2007 Oct; 48(10):1870-4. PubMed ID: 17634060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus.
    Zolkowska D; Wu CY; Rogawski MA
    Epilepsia; 2018 Oct; 59 Suppl 2(Suppl 2):220-227. PubMed ID: 29453777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy.
    Reddy DS; Rogawski MA
    J Pharmacol Exp Ther; 2000 Sep; 294(3):909-15. PubMed ID: 10945840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy.
    Lattanzi S; Riva A; Striano P
    Expert Rev Neurother; 2021 Nov; 21(11):1317-1332. PubMed ID: 33724128
    [No Abstract]   [Full Text] [Related]  

  • 9. Modification of behavioral effects of drugs in mice by neuroactive steroids.
    Ungard JT; Beekman M; Gasior M; Carter RB; Dijkstra D; Witkin JM
    Psychopharmacology (Berl); 2000 Mar; 148(4):336-43. PubMed ID: 10928304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate.
    Gasior M; Ungard JT; Beekman M; Carter RB; Witkin JM
    Neuropharmacology; 2000 Apr; 39(7):1184-96. PubMed ID: 10760361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence.
    Snead OC
    Ann Neurol; 1998 Oct; 44(4):688-91. PubMed ID: 9778270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder.
    De SK
    Curr Med Chem; 2024; 31(4):388-392. PubMed ID: 36959132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone.
    Beekman M; Ungard JT; Gasior M; Carter RB; Dijkstra D; Goldberg SR; Witkin JM
    J Pharmacol Exp Ther; 1998 Mar; 284(3):868-77. PubMed ID: 9495844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.
    Chuang SH; Reddy DS
    J Pharmacol Exp Ther; 2020 Mar; 372(3):285-298. PubMed ID: 31843812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice.
    Kaminski RM; Livingood MR; Rogawski MA
    Epilepsia; 2004 Jul; 45(7):864-7. PubMed ID: 15230714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganaxolone.
    Nohria V; Giller E
    Neurotherapeutics; 2007 Jan; 4(1):102-5. PubMed ID: 17199022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism.
    Kazdoba TM; Hagerman RJ; Zolkowska D; Rogawski MA; Crawley JN
    Psychopharmacology (Berl); 2016 Jan; 233(2):309-23. PubMed ID: 26525567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurosteroids and Seizure Activity.
    Miziak B; Chrościńska-Krawczyk M; Czuczwar SJ
    Front Endocrinol (Lausanne); 2020; 11():541802. PubMed ID: 33117274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself.
    Reddy DS; Rogawski MA
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1241-8. PubMed ID: 11082461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone, 5a-dihydropogesterone and allopregnanolone's effects on seizures: A review of animal and clinical studies.
    Wu YV; Burnham WM
    Seizure; 2018 Dec; 63():26-36. PubMed ID: 30391663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.